You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歐康維視生物-B(01477.HK)中期虧損大幅收窄至6961萬元
格隆匯 08-20 22:46

格隆匯8月20日丨歐康維視生物-B(01477.HK)發佈公吿,截至2021年6月30日止六個月,公司收益2080萬元人民幣(上年同期為195萬元),期間虧損6961萬元,上年同期虧損17.42億元;每股虧損0.12元。

虧損同比下降96.0%,主要是由於(i)報吿期內按公平值計入損益的金融負債的公平值虧損為零,而2020年同期則為一次性公平值虧損人民幣1,511.7百萬元,此乃由於在上市後悉數轉換優先股;及(ii)來自EyePoint及Alimera交易的一次性收益人民幣115.2百萬元。

截至本公吿日期,公司的產品組合已擴充至包括18款藥物資產,全面覆蓋眼睛前部及眼睛後部疾病。公司正在開展五款候選藥物的六項III期臨牀試驗,其中兩款候選藥物處於國際III期MRCT,在向CDE申報進入III期臨牀試驗的候選藥物數量方面佔據領先地位。公司預期於本年度末,公司將有七款候選藥物處於臨牀試驗階段,其中六款候選藥物將處於III期臨牀試驗階段。進入III期臨牀試驗的候選藥物數量將確保公司業務的穩定增長及發展。

報吿期內,公司實現總醫院終端銷售收入人民幣27.74百萬元(未經審計),同比增長2,644.7%,公司繼續加快我們藥物滲透至中國眼科市場的醫院,覆蓋中國20多個省份。截至本公吿日期,公司的產品入駐醫院近800家。公司在江蘇、上海、山東、遼寧、重慶等重點省市建立強大而穩固的營銷網絡。預計到2021年末,公司的商業化團隊將擴大到150多人。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account